Quinoxaline 1,4-di-N-oxide derivatives and neglected diseases;Derivados de 1,4-di-N-óxido de quinoxalina y enfermedades olvidadas

Anales de la Real Academia Nacional de Farmacia

Volumn 73, Issue 4, 2007, Pages 927-945

  Vicente, Esther ^a   Villar, Raquel ^a   Solano, Beatriz ^a   Burguete, Asunción ^a   Ancizu, Saioa ^a   Pérez Silanes, Silvia ^a   Aldana, Ignacio ^a   Monge, Antonio ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Chagas; Developing countries; Leishmaniasis; Malaria; Tuberculosis

Indexed keywords

ANTIINFECTIVE AGENT; ANTILEISHMANIAL AGENT; ANTIMALARIAL AGENT; QUINOXALINE 1,4 DI N OXIDE DERIVATIVE; TUBERCULOSTATIC AGENT;

CHAGAS DISEASE; DRUG COST; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LEISHMANIASIS; MALARIA; MEDICAL RESEARCH; REVIEW; TUBERCULOSIS;

EID: 49149085591     PISSN: None     EISSN: 1697428X     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. CAINES, K. (2004) GHP study paper 4: Global health partnerships and neglected diseases. DFID Health Resource. London.
2. FEHR, A.; THURMANN, P. Y RAZUM, O. (2006) Editorial: Drug development for neglected diseases: a public health challenge. Trop. Med. Int. Health. 11: 1335-1338.
3. TROUILLER, P.; OLLIARO, P.; TORREELE, E.; ORBINSKI, J.; LAING, R. Y FORD, N. (2002) Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 359: 2188-2194.
4. DNDI (2005) Newsletter (11) Drugs for Neglected Diseases Initiative (DNDi), Geneva.
5. WORLD HEALTH ORGANIZATION. http://www.who.int/tdr.
6. LIMA, L. M. A. Y BARREIRO, E. J. (2005) Bioisosterism: A useful strategy for molecular modification and drug design. Curr. Med. Chem. 12: 23-49.
7. CIHAK, R. Y VONTORKOVA, M. (1985) Cytogenetic Effects of Quinoxaline-1,4-Dioxide-Type Growth-Promoting Agents. 3. Trans-Placental Micronucleus Test in Mice. Mutat. Res. 144: 81-84.
8. CIHAK, R. Y VONTORKOVA, M. (1985) Cytogenetic Effects of Quinoxaline-1,4-Dioxide-Type Growth-Promoting Agents Evaluated by the Trans-Placental Micronucleus Test. Mutat. Res. 147: 289-289.
9. GALI-MUHTASIB, H. U.; HADDADIN, M. J.; RAHHAL, D. N. Y YOUNES, I. H. (2001) Quinoxaline 1,4-dioxides as anticancer and hypoxia-selective drugs. Oncol. Rep. 8: 679-684.
10. MONGE, A.; PALOP, J. A.; DECERAIN, A. L.; SENADOR, V.; MARTINEZCRESPO, F. J.; SAINZ, Y.; NARRO, S.; GARCIA, E.; DEMIGUEL, C.; GONZALEZ, M.; HAMILTON, E.; BARKER, A. J.; CLARKE, E. D. Y GREENHOW, D. T. (1995) Hypoxia-Selective Agents Derived from Quinoxaline 1,4-Di-N-Oxides. J. Med. Chem. 38: 1786-1792.
11. AZQUETA, A.; PACHON, G.; CASCANTE, M.; CREPPY, E. E.; MONGE, A. Y DE CERAIN, A. L. (2005) Selective toxicity of a quinoxaline 1,4-di-N-oxide derivative in human tumour cell lines. Arzneim.-Forsch. 55: 177-182.
12. AZQUETA, A.; PACHON, G.; CASCANTE, M.; CREPPY, E. E. Y DE CERAIN, A. L. (2005) DNA damage induced by a quinoxaline 1,4-di-N-oxide derivative (hypoxic selective agent) in Caco-2 cells evaluated by the comet assay. Mutagenesis. 20: 165-171.
13. CHOWDHURY, G.; KOTANDENIYA, D.; DANIELS, J. S.; BARNES, C. L. Y GATES, K. S. (2004) Enzyme-activated, hypoxia-selective DNA damage by 3-amino-2-quinoxalinecarbonitrile 1,4-di-N-oxide. Chem. Res. Toxicol. 17: 1399-1405.
14. GANLEY, B.; CHOWDHURY, G.; BHANSALI, J.; DANIELS, J. S. Y GATES, K. S. (2001) Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide. Bioorg. Med. Chem. 9: 2395-2401.
15. AGUIRRE, G.; CERECETTO, H.; DI MAIO, R.; GONZALEZ, M.; ALFARO, M. E. M.; JASO, A.; ZARRANZ, B.; ORTEGA, M. A.; ALDANA, I. Y MONGE-VEGA, A. (2004) Quinoxaline NN′-dioxide derivatives and related compounds as growth inhibitors of Trypanosoma cruzi. Structure-activity YP relationships. Bioorg. Med. Chem. Lett. 14: 3835-3839.
16. URQUIOLA, C.; VIEITES, M.; AGUIRRE, G.; MARIN, A.; SOLANO, B.; ARRAMBIDE, G.; NOBLIA, P.; LAVAGGI, M. L.; TORRE, M. H.; GONZALEZ, M.; MONGE, A.; GAMBINO, D. Y CERECETTO, H. (2006) Improving anti-trypanosomal activity of 3-aminoquinoxaline-2-carbonitrile N-1,N-4-dioxide derivatives by complexation with vanadium. Bioorg. Med. Chem. 14: 5503-5509.
17. CARTA, A.; LORIGA, M.; PAGLIETTI, G.; MATTANA, A.; FIORI, P. L.; MOLLICOTTI, P.; SECHI, L. Y ZANETTI, S. (2004) Synthesis, anti-mycobacterial, anti-trichomonas and anti-candida in vitro activities of 2-substituted-6,7-difluoro-3-methylquinoxaline 1,4-dioxides. Eur. J. Med. Chem. 39: 195-203.
18. BROWN, D. J. (2004) Quinoxalines. Supplement II. Wiley & Sons. New York.
19. CARTA, A.; CORONA, P. Y LORIGA, M. (2005) Quinoxaline 1,4-dioxide: A versatile scaffold endowed with manifold activities. Curr. Med. Chem. 12: 2259-2272.
20. MONTOYA, M. E.; SAINZ, Y.; ORTEGA, M. A.; DE CERAIN, A. L. Y MONGE, A. (1998) Synthesis and antituberculosis activity of some new 2-quinoxalinecarbonitriles. Farmaco. 53: 570-573.
21. ORTEGA, M. A.; SAINZ, Y.; MONTOYA, M. E.; DE CERAIN, A. L. Y MONGE, A. (1999) Synthesis and antituberculosis activity of new 2-quinoxalinecarbonitrile 1,4-di-N-oxides. Pharmazie. 54: 24-25.
22. SAINZ, Y.; MONTOYA, M. E.; MARTINEZ- CRESPO, F. J.; ORTEGA, M. A.; DE CERAIN, A. L. Y MONGE, A. (1999) New quinoxaline 1,4-di-N-oxides for treatment of tuberculosis. Arzneim.-Forsch. 49: 55-59.
23. SANNA, P.; CARTA, A.; LORIGA, M.; ZANETTI, S. Y SECHI, L. (1999) Preparation and biological evaluation of 6/7-trifluoromethyl(nitro)-, 6,7-difluoro-3-alkyl (aryl)-substituted-quinoxalin-2-ones. Part 3. Farmaco. 54: 169-177.
24. ORTEGA, M. A.; MONTOYA, M. E.; JASO, A.; ZARRANZ, A.; TIRAPU, I.; ALDANA, I. Y MONGE, A. (2001) Antimycobacterial activity of new quinoxaline-2-carbonitriIe and quinoxaline-2-carbonitrile 1,4-di-N-oxide derivatives. Pharmazie. 56: 205-207.
25. ORTEGA, M. A.; SAINZ, Y.; MONTOYA, M. E.; JASO, A.; ZARRANZ, B.; ALDANA, I. Y MONGE, A. (2002) Anti-Mycobacterium tuberculosis agents derived from quinoxaline-2-carbonitrile and quinoxaline-2-carbonitrile 1,4-di-N-oxide. Arzneim.-Forsch. 52: 113-119.
26. ZARRANZ, B.; JASO, A.; ALDANA, I. Y MONGE, A. (2003) Synthesis and antimycobacterial activity of new quinoxaline-2-carboxamide 1,4-di-N-oxide derivatives. Bioorg. Med. Chem. 11: 2149-2156.
27. JASO, A.; ZARRANZ, B.; ALDANA, I. Y MONGE, A. (2003) Synthesis of new 2-acetyl and 2-benzoyl quinoxaline 1,4-di-N-oxide derivatives as anti-Mycobacterium tuberculosis agents. Eur. J. Med. Chem. 38: 791-800.
28. JASO, A.; ZARRANZ, B.; ALDANA, I. Y MONGE, A. (2005) Synthesis of new quinoxaline-2-carboxylate 1,4-dioxide derivatives as anti-Mycobacterium tuberculosis agents. J. Med. Chem. 48: 2019-2025.
29. GUILLON, J.; REYNOLDS, R. C.; LEGER, J. M.; GUIE, M. A.; MASSIP, S.; DALLEMAGNE, P. Y JARRY, C. (2004) Synthesis and preliminary in vitro evaluation of antimycobacterial activity of new pyrrolo[1,2-a]quinoxaline-carboxylic acid hydrazide derivatives. J. Enzyme Inhib. Med. Chem. 19: 489-495.
30. KUNES, J.; SPULAK, M.; WAISSER, K.; SLOSAREK, M. Y JANOTA, J. (2000) Quinoxaline derivatives as potential antituberculotic agents. Pharmazie. 55: 858-859.
31. SEITZ, L. E.; SULING, W. J. Y REYNOLDS, R. C. (2002) Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives. J. Med. Chem. 45: 5604-5606.
32. CARTA, A.; PAGLIETTI, G.; RAHBAR NIKOOKAR, M. E.; SANNA, P.; SECHI, L. Y ZANETTI, S. (2002) Novel substituted quinoxaline 1,4-dioxides with in vitro antimycobacterial and anticandida activity. Eur. J. Med. Chem. 37: 355-366.
33. GOLDMAN, R. C.; LAUGHON, B. E.; REYNOLDS, R. C.; SECRIST, J. A.; MADDRY, J. A.; GUIE, M. A.; POFFENBERGER, A. C.; KWONG, C. A. Y ANANTHAN, S. (2007) Programs to Facilitate Tuberculosis Drug Discovery: The Tuberculosis Antimicrobial Acquisition and Coordinating Facility. Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious). 7: 92-104.
34. FISHER, G. H.; MORENO, H. R.; OATIS, J. E. Y SCHULTZ, H. P. (1975) Quinoxaline Studies. 23. Potential Antimalarials - Substituted 5,8-dimethoxyquinoxalines. J. Med. Chem. 18: 746-752.
35. MORENO, H. R. Y SCHULTZ, H. P. (1970) Quinoxaline Studies. 15. Potential Antimalarials. Some (RS)-Alpha(Dialkylaminomethyl)-2- Quinoxalinemethanols. J. Med. Chem. 13: 119-121.
36. MORENO, H. R. Y SCHULTZ, H. P. (1970) Quinoxaline Studies. 17. Potential Antimalarials. 17. Some (RS)-Alpha-(Dialkylaminomethyl)- 6-Chloro-2-Quinoxalinemethanols. J. Med. Chem. 13: 1005-1008.
37. MORENO, H. R.; SCHULTZ, H. P. Y OATIS, J. E. (1972) Quinoxaline Studies. 20. Potential Antimalarials - Synthesis of Anti-N,N-Dialkylaminomethyl and SynN,N-Dialkylaminomethyl 2-Quinoxalinyl Ketoximes. J. Med. Chem. 15: 433-434.
38. DJUDOVIC, P.; MAIER, W.; PIEKARSKI, G.; SCHORNSTEIN, U. Y ZYMALKOWSKI, F. (1976) Synthesis of Quinoline-3-Derivatives and Quinoxaline-2-Derivatives and Their Actions against Various Malarial Parasites. Pharmazie 31: 845-849.
39. RANGISETTY, J. B.; GUPTA, C.; PRASAD, A. L.; SRINIVAS, P.; SRIDHAR, N.; PARIMOO, P. Y VEERANJANEYULU, A. (2001) Synthesis of new arylaminoquinoxalines and their antimalarial activity in mice. J. Pharm. Pharmacol. 53: 1409-1413.
40. ALDANA, I.; ORTEGA, M. A.; JASO, A.; ZARRANZ, B.; OPORTO, P.; GIMENEZ, A.; MONGE, A. Y DEHARO, E. (2003) Anti-malarial activity of some 7-chloro-2-quinoxalinecarbonitrile-1,4-di-N-oxide derivatives. Pharmazie. 58: 68-69.
41. ZARRANZ, B.; JASO, A.; ALDANA, I.; MONGE, A.; MAUREL, S.; DEHARO, E.; JULLIAN, V. Y SAUVAIN, M. (2005) Synthesis and antimalarial activity of new 3-arylquinoxaline-2-carbonitrile derivatives. Arzneim.-Forsch. 55: 754-761.
42. MARIN, A.; LIMA, L. M.; SOLANO, B.; VICENTE, E.; SILANES, S. P.; MAUREL, S.; SAUVAIN, M.; ALDANA, I.; MONGE, A. Y DEHARO, E. (2008) Antiplasmodial Structure-activity relationship of 3-trifluoromethyl-2-arylcarbonylquinoxaline 1,4-di-N-oxide derivatives. Exp. Parasitol. 118: 25-31.
43. ZARRANZ, B.; JASO, A.; LIMA, L. M.; ALDANA, I.; MONGE, A.; MAUREL, S. Y SAUVAIN, M. (2006) Antiplasmodial activity of 3-trifluoromethyl-2-carbonylquinoxaline di-N-oxide derivatives. Braz. J. Pharm. Sci. 42: 357-361.
44. GUILLON, J.; GRELLIER, P.; LABAIED, M.; SONNET, P.; LEGER, J. M.; DEPREZ-POULAIN, R.; FORFAR-BARES, I.; DALLEMAGNE, P.; LEMAITRE, N.; PEHOURCQ, F.; ROCHETTE, J.; SERGHERAERT, C. Y JARRY, C. (2004) Synthesis, antimalarial activity, and molecular modeling of new pyrrolo[1,2-a]quinoxalines, bispyrrolo[1,2-a]quinoxalines, bispyrido[3,2-e]pyrrolo[1,2-a] pyrazines, and bispyrrolo[1,2-a]thieno[3,2-e]pyrazines. J. Med. Chem. 47: 1997-2009.
45. CERECETTO, H.; DI MAIO, R.; GONZALEZ, M.; RISSO, M.; SAENZ, P.; SEOANE, G.; DENICOLA, A.; PELUFFO, G.; QUIJANO, C. Y OLEA-AZAR, C. (1999) 1,2,5-oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: Structure-activity relationships. J. Med. Chem. 42: 1941-1950.
46. LORIGA, M.; PIRAS, S.; PAGLIETTI, G.; COSTI, M. P. Y VENTURELLI, A. (2003) Quinoxaline chemistry. Part 15. 4-[2-Quinoxalylmethylenimino]-benzoylglutama-tes and -benzoates, 4-[2-quinoxalylmethyl-N-methylamino]-benzoylglutama-tes as analogues of classical antifolate agents. Synthesis, elucidation of structures and in vitro evaluation of antifolate and anticancer activities. Il Farmaco. 58: 51-61.
47. HUI, X.; DESRIVOT, J.; BORIES, C.; LOISEAU, P. M.; FRANCK, X.; HOCQUEMILLER, R. Y FIGADERE, B. (2006) Synthesis and antiprotozoal activity of some new synthetic substituted quinoxalines. Bioorg. Med. Chem. Lett. 16: 815-820.